The 53 references in paper O. Korennova Yu., L. Shukil' V., S. Mal'tsev N., I. Klinyshkov A., N. Leganova M., E. Turusheva A., T. Kropotina V., О. Кореннова Ю., Л. Шукиль В., С. Мальцев Н., И. Клинышков А., Н. Леганова М., Е. Турушева А., Т. Кропотина В. (2016) “Фармакоэкономическое обоснование применения генно-инженерных биологических препаратов в амбулаторных условиях // PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS” / spz:neicon:pharmacoeconomics:y:2016:i:1:p:39-48

1
Балабанова Р.М., Амирджанова В.Н., Насонов Е.Л. Применение генно-инженерных биологических препаратов при ревматоидном артрите в Российской Федерации. Науч-практич. ревматол. 2012; 50 (6): 10-14.
(check this in PDF content)
2
Бунчук Н.В. Инфликсимаб при анкилозирующем спондилите – STATUS PRAESENS. Науч-практич. ревматол. 2006; 4: 4-10.
(check this in PDF content)
3
Воробьев П.А., Авксентьева М.В., Юрьев А.С., Сура М.В. Клинико-экономический анализ (оценка, выбор медицинских технологий и управление качеством медицинской помощи). М. 2004; 404 с.
(check this in PDF content)
4
Выпуск клинических разборов в ревматологической практике. Учреждение Российской академии медицинских наук «Научноисследовательский институт ревматологии РАМН им. В.А. Насоновой», общероссийская общественная организация «Ассоциация ревматологов России». 2013; 136 с.
(check this in PDF content)
5
Годзенко А.А., Корсакова Ю.Л., Бадокин В.В. Методы оценки воспалительной активности и эффективности терапии при спондилоартритах. М. 2013; 48 с.
(check this in PDF content)
6
Карта-извещение о побочном действии, нежелательной реакции или отсутствии ожидаемого терапевтического эффекта лекарственного средства». Режим доступа: http://roszdravnadzor. ru/drugs/monitpringlp/documents/547. Дата обращения: 18.01.15
(check this in PDF content)
7
Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В.А. Насоновой Под ред. Е.Л. Насонова. Ревматология. Национальное руководство. М. 2008; 290-331.
(check this in PDF content)
8
Насонов Е.Л., Каратеев Д.Е. Применение генно-инженерных биологических препаратов для лечения ревматоидного артрита: общая характеристика (лекция). Науч-практич. ревматол. 2013; 51(2): 163-169.
(check this in PDF content)
9
Постановление Правительства Омской области от 24 декабря 2014 г. No 330-п «О Территориальной программе государственных гарантий бесплатного оказания гражданам медицинской помощи в Омской области на 2015 год и на плановый период 2016 и 2017 годов».
(check this in PDF content)
10
Приказ Минздрава России от 12 ноября 2012 г. No 900н «Об утверждении Порядка оказания медицинской помощи взрослому населению по профилю «Ревматология».
(check this in PDF content)
11
Приказ Минздрава России от 11 марта 2013 г. No 121н «Об утверждении Требований к организации и выполнению работ (услуг) при оказании первичной медико-санитарной, специализированной (в том числе высокотехнологичной), скорой (в том числе скорой специализированной), паллиативной медицинской помощи, оказании медицинской помощи при санаторно-курортном лечении, при проведении медицинских экспертиз, медицинских осмотров, медицинских освидетельствований и санитарно-противоэпидемических (профилактических) мероприятий в рамках оказания медицинской помощи, при трансплантации (пересадке) органов и (или) тканей, обращении донорской крови и (или) ее компонентов в медицинских целях».
(check this in PDF content)
12
Приказ Минздрава России от 2 декабря 2014 г. No 796н «Об утверждении Положения об организации оказания специализированной, в том числе высокотехнологичной, медицинской помощи».
(check this in PDF content)
13
Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М. 2002; 312 с.
(check this in PDF content)
14
Ревматология. Клинические рекомендации. Под ред. акад. РАМН Е.Л. Насонова. 2-е изд. М. 2010; 752 с.
(check this in PDF content)
15
Aaltonen K.J., Vikki L.M., Malmiaara A. et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in the treatment of rheumatoid arthritis. PLoS ONE. 2012; 7:e30275.
(check this in PDF content)
16
Alonso-Ruiz A., Pijoan J.I., Ansuategui E. et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders. 2008; 9: 52.
(check this in PDF content)
17
Baraliakos X., Listing J., Brandt J. et al. Persistent clinical response in patients with ankylosing spondylitis after 4 years of therapy with anti-TNF-monoclonal antibody infliximab. Ann. Rheum. Dis. 2005; 64 (3): 1055 (abstract).
(check this in PDF content)
18
Beevor C.P., Hull R., Thomas A. et al. Anti TNFa therapy reduce emergency health services usage. Ann Rheum Dis. 2006; 65 (II): 176.
(check this in PDF content)
19
Bergman G.J., Hochberg M.C., Boers M. et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to diseasemodifying antirheumatic drugs. Semin Arthritis Rheum. 2010; 39: 425-441.
(check this in PDF content)
20
Bongartz T., Sutton A.J., Sweeting M.J. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 17: 2275-2285.
(check this in PDF content)
21
Heijde D., Sieper J., Maksymowych W. et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 2011; 70: 905-8. DOI:10.1136/ard.2011.151563.
(check this in PDF content)
22
Devine E.B., Alfonso-Cristanchp R., Sullivan S.D. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy. 2011; 31: 39-51.
(check this in PDF content)
23
Fransen J., Stucki G., van Reil P.L. Rheumatoid arthritis measures. Arthritis Rheum. 2003; 49: 214-24.
(check this in PDF content)
24
Gallego-Galisteo M., Villa-Rubio A., Alergre-del Rau E. et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2011; on line.
(check this in PDF content)
25
Garrett S.L., Jenkinson T.R., Whitelock H.C. et al. A new approach to defining disease status in ankylosing spondylitis: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J. Rheumatol. 1994; 21: 2286-91.
(check this in PDF content)
26
Gartlehner G., Hansen R.A., Jonas B.L. et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta-analysis. J Rheumatol. 2006; 3: 2398-2407l.
(check this in PDF content)
27
Gartlehner G., Thieda P., Morgan L.C. et al. Drug class review. Targeted Immune Modulators. Cecil G Sheps Center for Health Services Research. Oregon Health Science University. 2009.
(check this in PDF content)
28
Gomez-Reino J.J., Dasgupta B., Haugeberg G. et al. Mortality rate is reduced in RA patients treated with TNF antagonists. Data from Biobadaser. Ann Rheum Dis. 2006; 65 (II): 318.
(check this in PDF content)
29
Guyot P., Taylor P., Christensen R. et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Research Ther. 2011; 13: R204.
(check this in PDF content)
30
Kawalec P., Mikrut A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2013; 32: 1415-1424.
(check this in PDF content)
31
Kristensen L.E., Christensen R., Biddal H. et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systemic literature review. Scand J Rheumatol. 2007; 36: 411-417.
(check this in PDF content)
32
Kristensen L.E., Jakobsen A.K., Bartels E.M. et al. The number needed to treat for secondgeneration biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol. 2010; May 5.
(check this in PDF content)
33
Leombruno J.P., Einarson T.R., Keystone E.C. The safety of antitumor necrosis factor tretments in rheumatoid arthritis: meta and exposure adjusted pooled analysis of serious adverse events. Ann Rheum Dis. 2008; 27 Aug.
(check this in PDF content)
34
Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P. et al. Birmingham Vasculitis Activity Score (BVAS). Q.J.Med. 1994; 87 (11): 671-8.
(check this in PDF content)
35
Mandema J.W., Salinger D.H., Baumgartner S.W., Gibbs M.A. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol&Ther. 2011; 90: 828-835.
(check this in PDF content)
36
Mease P.J., Antoni C.E., Gladman D.D. et al. Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis. 2005; 64: 1149-54.
(check this in PDF content)
37
Nam J.L., Winthrop K.L., Van Vollenhoven et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010; 69: 976-986.
(check this in PDF content)
38
Nixon R.M., Bansback N., Brennan A. Using mixed treatment comparison and meta-regression to perform indirect comparisons to estimate efficacy of biologic treatment in rheumatoid arthritis. Stat Med. 2007; 26: 1237-1254.
(check this in PDF content)
39
Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan; 38 (1): 44-8. DOI: http://dx.doi.org/10.1002/art.1780380107.
(check this in PDF content)
40
Roy S. Cifaldi M.A. Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate: a mixed treatment comparison meta-analysis. Ann Rheum Dis. 2011; 70 (3): 432.
(check this in PDF content)
41
Salgado E., Maneiro J.R., Carmona L. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and metaanalysis. Ann Rheum Dis. DOI:10.1136/annrheumdis-2012-203116.
(check this in PDF content)
42
Salliot C., Finckh A., Katchamart W. et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta- analysis. Ann Rheum Dis. 2011; 70: 266-271.
(check this in PDF content)
43
Schmitz S., Adams R., Walsh C. et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatment: a Bayesian approach. Ann Rheum Dis. 2012; 71: 225-230.
(check this in PDF content)
44
Schmitz S., Adams R., Walsh C.D. et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrated differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012; January 31.
(check this in PDF content)
45
Singh J.A., Christensen R., Wells G.A. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. The Cochrane Library. 2009; 4.
(check this in PDF content)
46
Singh J.A., Wells G.A., Christensen R. et al. Adverse effects of biologics: a network metaanalysis and Cochrane overview (Review). The Cocgrane Library. 2011; 2.
(check this in PDF content)
47
Singh J.A., Wells G.A., Christensen R. et al. Adverse effects of biologics: a network metaanalysis and Cochrane overview (Review). The Cocgrane Library. 2012; 3.
(check this in PDF content)
48
Turksta E., Ng S.-K., Scuffham P.A. A mixed treatment comparison of the short-term efficacy of biologic disease modifying antirheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011; 27: 1885-1897.
(check this in PDF content)
49
Gestel A.M., Haagsma C.J., van Riel P.L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998; 41 (10): 1845-50.
(check this in PDF content)
50
Vieira M.C., Wallenstein G., Bradley J. et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis facto inhibitors – a network meta-analisis. Ann Rheum Dis. 2014; 72 (3): 619.
(check this in PDF content)
51
Vieira M.C., Wallenstein G., Bradley J. et al. Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs – a network meta-analysis. Ann Rheum Dis. 2012; 71 (3): 375.
(check this in PDF content)
52
Wiens A., Venson R., Pharm D. et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010; 30: 339-353.
(check this in PDF content)
53
Yazici Y., Moniz Reed D., Rosenblatt L. et al. Number needed to treat (NNT) analysis of randomized controlled trials (RCTS) of biologics in methotrexate-naive patients with early rheumatoid arthritis. Ann Rheum Dis. 2009; 68 (3): 583.
(check this in PDF content)